81 results
8-K/A
EX-99.4
CELU
Celularity Inc - Ordinary Shares
16 Aug 21
Completion of Acquisition or Disposition of Assets
5:23pm
to continue to incur net losses for the foreseeable future, and it expects its research and development expenses, selling, general and administrative … clinical trials and its expenditures on other research and development activities.
Based upon Celularity’s current operating plan, Celularity does
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
10 Aug 22
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
12:00am
by increased product sales to our distribution partners.
Research and Development
Research and development expenses for the three months ended June 30 … clinical trial in advanced HER2 positive G/GEJ cancers for CYNK-101.
Research and development expenses for the six months ended June 30, 2022 increased
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
12 Nov 21
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
4:19pm
assets in August 2020.
Research and development expenses for the three months ended September 30, 2021 increased $12.5 million compared to the prior … year period. The increase in research and development expenses was primarily due to higher stock-based compensation expense resulting from awards granted
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
16 Aug 21
Celularity Reports Second Quarter 2021 Financial Results
5:20pm
generation software and computational capabilities to analyze Celularity’s cellular data and accelerate research and development activities.
On July 1 … with Sanuwave and (ii) an increase of $0.2 million in services revenues primarily due to higher biobanking storage revenues.
Research and development
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
10 Nov 22
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:19pm
to distribution partners.
Research and Development
Research and development expenses for the three months ended September 30, 2022, decreased … by approximately $3.4 million compared to the prior year period. The decrease was primarily due to a reduction in allocated costs.
Research and development
424B3
itq780km
10 Aug 22
Prospectus supplement
12:00am
424B3
zs05ur1z2lw
12 Nov 21
Prospectus supplement
4:45pm
424B3
0dujsv kr45kyn7
10 Aug 22
Prospectus supplement
12:00am
424B3
5ru43 fkdf
16 May 22
Prospectus supplement
8:20pm
8-K
EX-99.1
s692f9 c6
22 Jul 21
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
4:13pm
8-K/A
EX-99.3
i84f qr7w2ka02u69zy
16 Aug 21
Completion of Acquisition or Disposition of Assets
5:23pm